

-2-

Time and a check for the appropriate fee are being filed concurrently with this Amendment B.

Please amend the subject patent application as follows:

In the Title

Please amend the title to --METHODS OF PREVENTING OR TREATING THROMBOSIS WITH TUMOR NECROSIS FACTOR ANTAGONISTS--.

In the Specification

On page 8, line 20, delete "1994)," and insert --1994, now U.S. Patent No. 5,698,195,-- therefor.

On page 12, line 17, delete "1994)," and insert --1994, now U.S. Patent No. 5,698,195,-- therefor.

On page 17, line 18, delete "1994)," and insert --1994, now U.S. Patent No. 5,698,195,-- therefor.

On page 32, line 31, delete "1994)," and insert --1994, now U.S. Patent No. 5,698,195,-- therefor.

In the Claims

Please cancel Claims 11 and 33 and amend Claims 9, 10, 12, 13, 31, 32, 34 and 35 as follows:

b' (A) D?

9. (Twice Amended) A method of Claim 8 wherein the antibody is selected from the group consisting of: [a chimeric antibody,] a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

10. (Twice Amended) A method of Claim 8 [9] wherein the antibody binds to [one or more] an epitope[s] included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .

B²

12. (Amended) A method of Claim 8 [9] wherein the antibody is a chimeric antibody, wherein said chimeric antibody comprises

D&D

B²
cont
B³

a non-human variable region specific for TNF or an antigen-binding portion thereof and a human constant region.

B³
Antis

13. (Twice Amended) A method of Claim 12 wherein the chimeric antibody binds to [one or more] an epitope[s] included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .

B⁴

31. (Twice Amended) A method of Claim 30 wherein the antibody is selected from the group consisting of: [a chimeric antibody,] a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

B⁴
Antis

32. (Twice Amended) A method of Claim 30 [31] wherein the antibody binds to [one or more] an epitope[s] included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .

B⁵
Antis

34. (Amended) A method of Claim 30 [31] wherein the antibody is a chimeric antibody, wherein said chimeric antibody comprises a non-human variable region specific for TNF or an antigen-binding portion thereof and a human constant region.

B⁴
Antis

35. (Twice Amended) A method of Claim 34 wherein the chimeric antibody binds to [one or more] an epitope[s] included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .

REMARKS

The Examiner's withdrawal of several of the rejections made in Paper No. 8 under 35 U.S.C. § 112, first and second paragraphs, and the rejections under 35 U.S.C. § 102(b), 102(e) and 103(a) is acknowledged with appreciation.